Clinical Trial

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Study acronym: NEOPCOSCC
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2024 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy compared with TP chemotherapy or up-front surgery in resectable locally advanced oral squamous cell carcinoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-03-22; most recent amendment 2024-04-01.
Status change: Not Yet Recruiting → Recruiting 2024-02-02
Trial Details
NCT Number NCT05798793
Lead Sponsor Hospital of Stomatology, Wuhan University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Oral Squamous Cell Carcinoma
Enrollment 309 participants
Start Date 2023-11-21
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-02